David Taber, Pharm.D.
David J. Taber, Pharm.D., BCPS, joined MUSC in 2012 and is strongly committed to having a successful career focused in patient-oriented research; specifically with the goal of concentrating efforts to optimize medication outcomes within transplant recipients.
Dr. Taber’s current research endeavors surround the study of optimizing medication utilization in transplantation and studying mechanisms to improve the peri-operative value of care in transplant surgery. He is the PI of a R18 study with the U.S. Department of Health & Human Services, Agency for Healthcare Research and Quality (AHRQ) The amount awarded is $1,492,135 for the dates 9-1-17 – 6-30-20. The primary purpose of the Transplant Medication Safety through a Pharmacist-Empowered, Patient-Centered, mHealth-Based Intervention (TRANSAFE Rx) study is to demonstrate significant reductions in medication safety issues leading to reduced healthcare resource utilization in kidney transplantation through a pharmacist led, mHealth-enabled, intervention.
Dr. Taber was recetly recognized by his peers as recipient of the 2017 Distinguished Investigator Award by the American College of Clinical Pharmacists.
About Dave Taber
Dr. Taber graduated cum laude and a member of the Dean’s list with a BS in Pharmacy from the State University of New York at Buffalo, one of the top pharmacy programs in the country. He was one of a handful of out-of-state applicants accepted into the post-baccalaureate PharmD program at the Medical University of South Carolina (MUSC). This program is known for its diverse training opportunities with innovative clinical pharmacy practice.
He graduated second in his class from MUSC, which aided in obtaining a post-doctorate pharmacy residency in transplant at the University of North Carolina (UNC) at Chapel Hill. Dr. Taber has approximately 15 years of post-residency experience providing pharmaceutical care to transplant patients. He has a strong record of collaborating in research endeavors surrounding the study of medication optimization in transplant recipients.
Dr. Taber has a long-standing and deep seeded interest in conducting research. During his undergraduate education, he worked for Dr. Bauer analyzing the pharmaceutical properties of liposomal nitric oxide synthase inhibitors; through his doctorate training, he worked with Dr. White analyzing the pharmacokinetic and pharmacodynamic properties of the respiratory fluoroquinolones. Subsequently, Dr. Taber’s interest in conducting clinical research blossomed into a career passion through his clinical experiences with patient care. Dr. Taber’s academic training enabled him to gain a solid foundation in clinical pharmacy practice and collaborate with colleagues in clinical research. This training provided a rich and diverse flavor for clinical research.